Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esketamine - Johnson & Johnson

Next Previous
X
Search
Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: Esketamine nasal spray; JNJ-54135419; JNJ-54135419-AAA; JNJ-5419; S-ketamine; SPRAVATO

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 22 Jul 2024 Preregistration for Major depressive disorder (Treatment-resistant, Monotherapy) in USA (Intranasal)
  • 08 Oct 2023 Updated safety and efficacy data from a phase III ESCAPE-TRD trial in Major Depressive disorder presented at the 36th European College of Neuropsychopharmacology Congress (ECNP-2023)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Belgium (Sublingual, Film)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top